Unknown PHASE2 INTERVENTIONAL 2-arm NCT06297369

Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients

Sponsor: Ain Shams University

Conditions Cancer Patients Cisplatin Adverse Reaction Cisplatin Induced Peripheral Neuropathy Cisplatin Nephrotoxicity Cisplatin Ototoxicity

Interventions N acetyl cysteine

Updated 4 times since 2024 Last updated: Feb 29, 2024 Started: Feb 1, 2024 Primary completion: Feb 1, 2025 Completion: Aug 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cancer Patients and Cisplatin Adverse Reaction and is currently ongoing. Ain Shams University leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ain Shams University

Data source: Ain Shams University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt